Tesamorelin in Tennessee: FDA-Approved GHRH for Visceral Fat

Why Visceral Fat Matters

Not all fat is equal. Subcutaneous fat (under the skin) is largely cosmetic. Visceral fat — the deep abdominal fat packed around the liver, pancreas, and intestines — is metabolically active. It secretes inflammatory cytokines, drives insulin resistance, and is strongly associated with cardiovascular disease, type 2 diabetes, and metabolic syndrome.

Standard weight loss diets reduce visceral and subcutaneous fat proportionally. Tesamorelin is one of the few interventions shown to preferentially reduce visceral fat — making it relevant for patients with central obesity even at normal BMI.

Mechanism of Action

Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating somatotroph cells to produce and release growth hormone in natural pulses. GH then stimulates the liver to produce IGF-1. The GH/IGF-1 axis promotes lipolysis (fat breakdown), particularly in visceral adipose tissue, while preserving lean muscle mass.

Because GH is released in response to tesamorelin (not injected directly), the pituitary's negative feedback remains intact — GH cannot over-accumulate, reducing acromegaly risk.

GHRH Peptide Comparison

Cost in Tennessee

Compounded tesamorelin runs $200–350/month from a Tennessee-licensed pharmacy. Brand Egrifta is expensive and rarely covered outside its approved HIV indication. Consultation fees are $99–199. See our full cost guide.